Trial Profile
An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Dermatitis
- Focus Therapeutic Use
- 09 Jan 2023 Planned End Date changed from 1 Mar 2020 to 1 Aug 2019.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2019 to 1 Aug 2019.
- 09 Jan 2023 Planned initiation date changed from 1 Feb 2019 to 28 Feb 2019.